Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris

NCT ID: NCT02651220

Last Updated: 2020-06-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 1001 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-11-30
• Study Completion Date: 2016-10-31

Brief Summary

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of adapalene and benzoyl peroxide gel, 0.3%/2.5% (Actavis Laboratories UT, Inc.) to Epiduo® Forte (adapalene and benzoyl peroxide) gel 0.3%/2.5% (Galderma) in the treatment of Acne Vulgaris

Detailed Description

Up to 1000 patients 12 to 40 years of age inclusive will be enrolled to have 870 patients in the modified intent-to-treat (mITT) population and 579 patients in the per-protocol (PP) population. The primary inclusion criteria are the presence of ≥ 20 inflammatory lesions (papules and pustules) and ≥ 25 non-inflammatory lesions (opened and closed comedones) and ≤ 2 nodulocystic lesions (i.e., nodules and cysts) on the face and an Investigator's Global Assessment (IGA) score of 3 or 4.

Eligible patients will be randomized in a 1:1:1 ratio to one of the three treatments (Test, Reference or Placebo) on Visit 1. Patients will be instructed to apply the first treatment on the evening of enrollment into the study and then continue to apply once daily for the next 83 days (for a total 84 days). Patients will attend the following scheduled clinic visits:

• Visit 1 - Screening/Baseline: Day 1
• Visit 2 - Interim Visit: Day 28 ± 4
• Visit 3 - Interim Visit: Day 56 ± 4
• Visit 4 - End of Study: Day 85 ± 4 Efficacy evaluations will be based on dermatological assessments in the clinic. The primary statistical analyses of interest are (1) the percent change from baseline to Week 12 in the number of inflamed (papules/pustules) lesions and non-inflamed (open and closed comedones) lesions. In addition, patients will also be evaluated by the Investigator to determine "Clinical Success" or "Clinical Failure" at Week 12

Conditions

Acne

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w

Group Type: EXPERIMENTAL

Adapalene and Benzoyl Peroxide Gel

Intervention Type: DRUG

Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w

Epiduo® Forte Gel 0.3%/2.5% w/w

Group Type: ACTIVE_COMPARATOR

Epiduo® Forte Gel

Intervention Type: DRUG

Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w

Placebo (vehicle) Topical Gel

Group Type: PLACEBO_COMPARATOR

placebo gel

Intervention Type: DRUG

vehicle used as placebo

Interventions

Epiduo® Forte Gel

Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w

Intervention Type: DRUG

Adapalene and Benzoyl Peroxide Gel

Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w

Intervention Type: DRUG

placebo gel

vehicle used as placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or non-pregnant, non-lactating female, ≥ 12 and ≤ 40 years of age with a clinical diagnosis of acne vulgaris.

2. Signed informed consent form that meets all criteria of current FDA regulations. For a patient considered to be a minor in the state he/she lives and is enrolled, the patient parent or legal guardian will be required to sign the consent form and the patient will sign an IRB approved "assent to participate" form.

3. Females of child bearing potential must not be pregnant or lactating at Visit 1 (as confirmed by a negative urine pregnancy test with a sensitivity of less than 25 mlU/mL or equivalent units of human chorionic gonadotropin). Women of childbearing potential must agree to the use of a reliable method of contraception (e.g., total abstinence, IUD, a double-barrier method [such as condom plus diaphragm with spermicide], oral, transdermal, injected or implanted non- or hormonal contraceptive), throughout the study. If the female is using a hormonal contraceptive, the same product must be taken for 3 months prior to Visit 1 and must agree not to replace with some other hormonal contraceptives during the study. A sterile sexual partner is not considered an adequate form of birth control.

All females will be considered to be of childbearing potential unless they:

• Are post-menopausal, defined as women who have been amenorrheic for at least 12 consecutive months, without other known or suspected primary cause.
• Have been sterilized surgically or who are otherwise proven sterile (i.e., total hysterectomy, or bilateral oophorectomy) with surgery at least 4 weeks prior to Screening. Tubal ligation will not be considered a surgically sterile method.

Female patients of childbearing potential are defined as:

• Females without prior hysterectomy, or who have had any evidence of menses in the past 12 months.
• Females who have been amenorrhea for ≥ 12 months, but the amenorrhea is possibly due to other causes, including prior chemotherapy, anti-estrogens, or ovarian suppression.

4. Have facial acne vulgaris with: ≥ 20 inflammatory lesions (i.e., papules and pustules) and ≥ 25 non-inflammatory lesions (i.e., open and closed comedones) and ≤ 2 nodulocystic lesions (i.e., nodules and cysts).

5. Have an Investigator's Global Assessment (IGA) score of 3 or 4 (see Appendix A).

6. Willing to comply with the study requirements and restrictions including refraining from the use of all other topical acne medications or antibiotics during the 12 week treatment period.

7. Patients who use make-up must have used the same brands/types for a minimum period of 14 days before study entry and must agree to not change brand/type or frequency of use throughout the study.

Exclusion Criteria

1. Patient has more than 2 facial nodular lesions; any nodules present will be documented but not included in the inflammatory and non-inflammatory lesion count for analysis.

2. Patient has active cystic acne.

3. Patient has acne conglobata, acne fulminans, or acne vulgaris requiring systemic treatment.

4. Patient has a skin condition that would interfere with the diagnosis or assessment of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid folliculitis, bacterial folliculitis).

5. Patients with excessive facial hair such as beards, sideburns, moustaches, etc. that would interfere with the diagnosis or assessment of acne.

6. Patients with tattoos or excessive facial scarring that, in the Investigator's opinion, may interfere with the evaluation of the patient's acne.

7. Patients with active facial sunburn, peeling from sunburn, or patients that will be exposed to excessive sunlight during the study.

8. Females who are pregnant, lactating or likely to become pregnant during the study.

9. History of allergy or hypersensitivity to adapalene, retinoids, benzoyl peroxide or history of any drug hypersensitivity or intolerance that, in the Investigator's opinion, would compromise the safety of the patient or the study.

10. Significant history or current evidence of chronic infectious disease, system disorder, organ disorder or other medical condition that, in the Investigator's opinion, would place the study participant at undue risk by participation.

11. Use of the following on the face within 1 month before Screening/Baseline:

• Cryodestruction or chemodestruction
• Dermabrasion
• Photodynamic therapy
• Acne surgery
• Intralesional steroids
• X-ray therapy

12. Use of the following within 1 month before Screening/Baseline:

• Spironolactone
• Systemic steroids
• Systemic antibiotics
• Systemic anti-inflammatory agents (the use of acetylsalicylic acid for prophylactic use up to 325 mg/day is allowed, provided that the patient is on a stable dose and the regimen will remain constant throughout the study). Acetaminophen will be allowed during the study with a maximum dose of 1g (i.e., 1000 mg) twice daily and for a maximum of 3 consecutive days (its use is not allowed within 1 week of each visit).
• Systemic treatment for acne vulgaris (other than oral retinoids that require a 6 month washout), including anti-androgens.

13. Use of oral isotretinoin (Accutane®) or oral retinoids within 6 months, or therapeutic vitamin A supplements greater than 10,000 units/day (multivitamins are allowed).

14. Use of the following on the face within 2 weeks before Screening/Baseline:

• Topical steroids
• Topical retinoids
• Topical zinc
• Topical anti-inflammatory agents (including salicylic acid)
• Topical antibiotics (including antibacterials)
• Benzoyl peroxide
• Any other topical over-the-counter preparations for acne treatment

15. Use of the following on the face within 1 week before Screening/Baseline:

• Phototherapy devices for acne (e.g., ClearLightTM)
• Medicated cleansers including adhesive cleansing strips
• Cosmetic procedures (i.e., facials, peeling, comedone extraction) and alpha-hydroxy/glycolic acid

16. Receipt of any drug as part of a research study within 30 days.

17. Female patients taking hormonal contraceptives or oral estrogen for less than three months and those that plan to change the dosage regimen during the course of the study.

18. Previous participation in this study.

19. Employees of the Investigator or research center or their immediate family members.

20. Patients who are illiterate.

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Actavis Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Site 103

Mesa, Arizona, United States

Site 109

Tucson, Arizona, United States

Site 112

Anaheim, California, United States

Site 110

Long Beach, California, United States

Site 111

Los Angeles, California, United States

Site 104

San Diego, California, United States

Site 113

West Covina, California, United States

Site 101

Brandon, Florida, United States

Site 119

Jacksonville, Florida, United States

Site 114

Miami, Florida, United States

Site 115

Miami, Florida, United States

Site 116

Miramar, Florida, United States

Site 102

Arlington Heights, Illinois, United States

Site 105

Carmel, Indiana, United States

Site 120

New Albany, Indiana, United States

Site 107

Henderson, Nevada, United States

Site 106

High Point, North Carolina, United States

Site 108

Rhinelander, Wisconsin, United States

Site 117

Belize City, , Belize

Site 118

Belize City, , Belize

Countries

United States; Belize

Other Identifiers

71491705

Identifier Type: -

Identifier Source: org_study_id